Capivasertib (also known as Truqap) is an innovative drug that is widely recognized internationally, especially in the treatment of specific types of breast diseases. However, its use is not without restrictions, and the indications, contraindications and dietary requirements for patients must be strictly followed.
Indications of Capivasertib
Capivasertib is a targeted therapy drug with specific and clear indications, mainly for patients with specific types of breast diseases.
Precision treatment for breast diseases
Capivasertib combined with fulvestrant is suitable for patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast diseases. These patients need to be tested to confirm the presence of genetic changes such as PIK3CA/AKT1/PTEN, and relapse in a short period of time after endocrine therapy failure or after completion of adjuvant therapy.
Improve treatment effect and quality of life
The precise treatment strategy of Capivasertib not only helps to improve the treatment effect, but also prolongs the patient's survival and improves their quality of life to a certain extent. By intervening against specific genetic characteristics, Capivasertib provides new treatment hope for patients with breast diseases.
The indications of Capivasertib focus on patients with specific types of breast diseases, and its precision treatment strategy brings new treatment options and hope to patients.
Contraindications of Capivasertib
Although Capivasertib has shown significant efficacy in the treatment of breast diseases, its use is not suitable for all patients. Understanding the contraindications of Capivasertib is important for patient safety.
Use with caution in specific populations
Pregnant women, breastfeeding women, and patients who are allergic to Capivasertib or its ingredients should not use this drug. In addition, because Capivasertib may cause harm to the fetus, women with reproductive potential should take effective contraceptive measures during use.
Risk of drug interactions
There is a risk of interaction between Capivasertib and drugs such as strong CYP3A inhibitors, which may lead to abnormally high drug concentrations and increase the risk of adverse reactions. Therefore, during the use of Capivasertib, patients should avoid taking these drugs at the same time.
The contraindications of Capivasertib involve specific populations and the risk of drug interactions. Understanding and following these contraindications is the key to the safe use of Capivasertib by patients.
Contraindications for Capivasertib patients
During the use of Capivasertib, patients should also pay special attention to their diet. Certain foods may interact with drugs, affect drug efficacy or increase the risk of adverse reactions.
Avoid high-sugar foods
Since Capivasertib may cause adverse reactions such as hyperglycemia, patients should avoid high-sugar foods, such as candy, sweet drinks, etc. during use. These foods may aggravate blood sugar fluctuations and increase the risk of adverse reactions.
Be cautious in eating foods that affect drug metabolism
Certain foods, such as grapefruit and grapefruit juice, may affect the activity of CYP3A enzymes, thereby affecting the metabolism and excretion of Capivasertib. Therefore, patients should be cautious in eating these foods during the use of Capivasertib to avoid affecting the efficacy of the drug.
During the use of Capivasertib, patients need to pay special attention to dietary taboos, avoid high-sugar foods and foods that may affect drug metabolism, and follow the doctor's advice.
